ERBB2 and breast carcinoma: Approval in breast cancer was granted based on results from the APHINITY trial (NCT01358877), a multicenter, randomized, double-blind, placebo-controlled study involving 4804 patients with HER2-positive early breast cancer who had undergone surgical removal of the primary tumor prior to randomization [125].